In addition to KIAA1549, many other proteins have been reported as fusion partners to BRAF in glioma, all consisting of an N-terminal dimerization domain from another protein and the C-terminal kinase domain of BRAF, thereby removing the regulatory domain of BRAF without impairing its ability to dimerize (Table 1). This evidence concerns the gene KIAA1549 and central nervous system cancer.